Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | ALNY |
---|---|---|
09:32 ET | 4694 | 265.035 |
09:34 ET | 713 | 265 |
09:36 ET | 13500 | 264.585 |
09:39 ET | 100 | 265.93 |
09:41 ET | 400 | 264.39 |
09:45 ET | 2178 | 264.865 |
09:48 ET | 2200 | 265.32 |
09:50 ET | 1670 | 265.94 |
09:52 ET | 200 | 266.04 |
09:54 ET | 400 | 267.03 |
09:56 ET | 100 | 266.5 |
09:57 ET | 623 | 266.475 |
09:59 ET | 200 | 266.44 |
10:01 ET | 1308 | 266.440445 |
10:03 ET | 1337 | 265.89 |
10:06 ET | 753 | 265.63 |
10:08 ET | 170 | 266.27 |
10:10 ET | 842 | 266.45 |
10:12 ET | 100 | 266.45 |
10:15 ET | 2000 | 266.335 |
10:17 ET | 1326 | 266.88 |
10:19 ET | 700 | 266.525 |
10:24 ET | 1500 | 266.34 |
10:26 ET | 1800 | 266.24 |
10:28 ET | 400 | 265.8 |
10:30 ET | 400 | 265.775 |
10:32 ET | 4109 | 265.68 |
10:33 ET | 400 | 265.855 |
10:35 ET | 1000 | 265.83 |
10:37 ET | 800 | 266.3 |
10:39 ET | 1100 | 266.275 |
10:42 ET | 100 | 266.335 |
10:46 ET | 200 | 267.145 |
10:48 ET | 650 | 267.2177 |
10:50 ET | 200 | 267.335 |
10:51 ET | 100 | 267.095 |
10:53 ET | 400 | 267.57 |
10:55 ET | 400 | 267.45 |
10:57 ET | 7224 | 266.41 |
11:00 ET | 700 | 266.89 |
11:02 ET | 400 | 266.31 |
11:04 ET | 100 | 266.31 |
11:06 ET | 300 | 265.79 |
11:08 ET | 503 | 266.225 |
11:09 ET | 100 | 265.95 |
11:11 ET | 1001 | 265.935 |
11:13 ET | 2534 | 266.865 |
11:15 ET | 2326 | 266.855 |
11:20 ET | 100 | 266.93 |
11:22 ET | 200 | 267.34 |
11:24 ET | 200 | 267.25 |
11:26 ET | 100 | 267.035 |
11:27 ET | 100 | 267.015 |
11:31 ET | 901 | 267.1 |
11:36 ET | 1700 | 267.59 |
11:38 ET | 463 | 267.595 |
11:40 ET | 1100 | 267.595 |
11:42 ET | 100 | 267.9 |
11:44 ET | 682 | 268.09 |
11:45 ET | 900 | 268.01 |
11:47 ET | 1000 | 267.885 |
11:54 ET | 3273 | 268.14 |
11:56 ET | 657 | 268.51 |
11:58 ET | 801 | 268.445 |
12:00 ET | 300 | 268.4925 |
12:02 ET | 500 | 268.59 |
12:03 ET | 317 | 268.645 |
12:05 ET | 200 | 268.65 |
12:09 ET | 616 | 268.86 |
12:12 ET | 2051 | 268.27 |
12:14 ET | 584 | 267.885 |
12:16 ET | 875 | 268.05 |
12:18 ET | 726 | 267.69 |
12:20 ET | 1155 | 267.84 |
12:21 ET | 167 | 267.8575 |
12:25 ET | 741 | 268.382 |
12:27 ET | 200 | 268.48 |
12:30 ET | 430 | 268.515 |
12:32 ET | 17900 | 268.66 |
12:34 ET | 4530 | 267.97 |
12:36 ET | 200 | 267.99 |
12:39 ET | 700 | 268.52 |
12:45 ET | 1400 | 268.77 |
12:48 ET | 410 | 268.69 |
12:50 ET | 100 | 268.96 |
12:52 ET | 900 | 269.145 |
12:54 ET | 200 | 269.245 |
12:56 ET | 200 | 269.245 |
12:57 ET | 200 | 269.73 |
12:59 ET | 200 | 269.74 |
01:01 ET | 11976 | 270.1 |
01:06 ET | 500 | 270.13 |
01:08 ET | 300 | 270.1 |
01:10 ET | 200 | 270.095 |
01:12 ET | 220 | 270.265 |
01:14 ET | 1707 | 270.42 |
01:15 ET | 400 | 270.43 |
01:17 ET | 3306 | 270.43 |
01:19 ET | 1914 | 270.335 |
01:21 ET | 2085 | 270.2525 |
01:24 ET | 800 | 270.39 |
01:26 ET | 1830 | 270.65 |
01:28 ET | 1948 | 270.74 |
01:30 ET | 1000 | 270.915 |
01:32 ET | 209 | 271.07 |
01:35 ET | 635 | 270.74 |
01:37 ET | 100 | 271.03 |
01:39 ET | 200 | 270.77 |
01:42 ET | 300 | 270.77 |
01:44 ET | 526 | 270.405 |
01:46 ET | 174 | 270.375 |
01:48 ET | 300 | 270.54 |
01:50 ET | 100 | 270.27 |
01:51 ET | 1350 | 270.71 |
01:53 ET | 1096 | 270.855 |
01:55 ET | 1434 | 270.58 |
01:57 ET | 640 | 270.82 |
02:02 ET | 1939 | 270.47 |
02:04 ET | 600 | 270.615 |
02:06 ET | 100 | 270.62 |
02:08 ET | 600 | 270.44 |
02:09 ET | 100 | 270.445 |
02:11 ET | 400 | 270.465 |
02:13 ET | 100 | 270.465 |
02:20 ET | 200 | 270.565 |
02:22 ET | 600 | 270.81 |
02:24 ET | 200 | 270.52 |
02:26 ET | 1100 | 270.69 |
02:29 ET | 594 | 270.49 |
02:31 ET | 956 | 270.55 |
02:33 ET | 2100 | 270.32 |
02:36 ET | 400 | 270.46 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Alnylam Pharmaceuticals Inc | 34.1B | -430.3x | --- |
argenx SE | 32.3B | -154.6x | --- |
Beigene Ltd | 22.0B | -38.6x | --- |
Biontech SE | 29.3B | -53.7x | --- |
Biomarin Pharmaceutical Inc | 16.2B | 53.3x | --- |
Neurocrine Biosciences Inc | 12.3B | 37.1x | +62.04% |
Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $34.1B |
---|---|
Revenue (TTM) | $2.3B |
Shares Outstanding | 128.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.38 |
EPS | $-0.63 |
Book Value | $-1.75 |
P/E Ratio | -430.3x |
Price/Sales (TTM) | 14.5 |
Price/Cash Flow (TTM) | --- |
Operating Margin | 4.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.